Ascendis Pharma A/S
ASND · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.96 | -0.16 | 0.83 | 1.72 |
| FCF Yield | -0.13% | -0.17% | -1.10% | -0.72% |
| EV / EBITDA | 3,946.58 | -202.87 | -217.60 | -112.68 |
| Quality | ||||
| ROIC | -9.55% | -15.83% | 0.05% | -13.86% |
| Gross Margin | 80.10% | 82.65% | 91.94% | 80.63% |
| Cash Conversion Ratio | -0.04 | 0.19 | 0.15 | 2.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 62.06% | 60.29% | 67.87% | 92.25% |
| Free Cash Flow Growth | 22.22% | 82.85% | -54.61% | 8.14% |
| Safety | ||||
| Net Debt / EBITDA | 128.71 | -7.45 | -7.84 | -2.29 |
| Interest Coverage | -1.60 | -2.33 | -0.01 | -3.82 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.06 | 0.05 | 0.04 |
| Cash Conversion Cycle | 662.94 | 1,131.73 | 1,364.62 | 1,579.48 |